Navigation Links
Common treatment for men's pelvic pain proves ineffective, Queen's-led study shows
Date:12/18/2008

Kingston, ON A commonly-prescribed drug for men suffering from a painful pelvic condition failed to significantly reduce patients' symptoms in an international study led by Queen's University professor and urologist at Kingston General Hospital, Curtis Nickel.

The drug, called Alfuzosin, is regularly prescribed by more than half of family doctors to treat chronic prostititis/chronic pelvic pain syndrome. This affliction is estimated to affect from six to 12 per cent of the population.

Sponsored by the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, the study is published today in the prestigious New England Journal of Medicine.

"The results of our study will inform not only future clinical trials of alpha-blockers, but also other potential therapies," says Dr. Nickel, who is Canada Research Chair in Urologic Pain and Inflammation.

"Although the evidence for using alpha-blockers to treat new cases of chronic prostatitis/chronic pelvic pain syndrome is weak, some physicians have advocated use of this class of drug in men with this condition," he adds. "Our findings do not support this recommendation and should prompt reconsideration of use of an alpha-blocker as the first drug of choice for these patients."

Prostatitis is a common and costly medical condition, with chronic prostatitis/chronic pelvic pain syndrome the most frequent type seen by physicians. Men with this condition experience pain in the genital and urinary tract area and also report lower urinary tract symptoms and sexual problems that negatively affect their quality of life.

In the Queen's-led study, 233 men diagnosed with chronic prostatitis/chronic pelvic pain syndrome were randomly assigned to either alfuzosin or an identical-looking placebo. None of the men had received prior treatment with a beta-blocker.

Over the 12-week trial, participants wer
'/>"/>

Contact: Nancy Dorrance
nancy.dorrance@queensu.ca
Queen's University
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Common treatment for chronic prostatitis fails to reduce symptoms
2. Common infant virus may trigger type 1 diabetes
3. Migraines: Help for a common problem in children and teenagers
4. Latino Psychologist Appointed to Mental Health Post in Commonwealth
5. PA Department of Health Revokes Hospital License for Commonwealth Medical Center in Beaver County
6. Two common diabetes drugs double the risk of fractures in women
7. Brain Boosting Drugs vs. Walking: Treadmill Desk Manufacturer Promotes Common Sense
8. Encision Announces Quoting of Common Stock on the OTC Bulletin Board
9. Self-Dosing Pain Medication Errors Too Common: Study
10. A book of common prayers
11. Study finds treatment fails to improve common form of heart failure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common treatment for men's pelvic pain proves ineffective, Queen's-led study shows
(Date:3/31/2015)... March 31, 2015 The report ... (Reagents, Standards), Test Type (APTT, Prothrombin Time/INR, D-Dimer, ... Hospital)–Forecast to 2019” analyzes and studies the major ... America, Europe, Asia-Pacific and the Rest of the ... market is expected to reach $3.58 billion by ...
(Date:3/31/2015)... California (PRWEB) March 31, 2015 ... company that specializes in providing online solutions ... announced today it has achieved full accreditation ... Healthcare Network Accreditation Program (HNAP) from the ... , EHNAC’s HNAP accreditation runs in two-year ...
(Date:3/31/2015)... Diane Blackburn-Zambetti is the Director of ... Research Foundation (Meso Foundation). Blackburn-Zambetti will present an ... the BoRit Asbestos Superfund Citizen Advisory Group Meeting ... discuss anatomy, six types of asbestos, asbestos products, ... prevention and proper communication with your healthcare provider. ...
(Date:3/31/2015)... 2015 Dr. Stewart Shofner of ... sunshine; however, it's important to be aware of hazards related ... say more than 90 percent of eye injuries can ... safety glasses. Dr. Shofner shares five popular activities and important ... Yard Work. While using a lawn mower, leaf-blower, weed trimmer, ...
(Date:3/31/2015)... 2015 In a normal year for ... are anxiously awaited. After a winter of waiting, cabin ... winter snowpack in the mountain high country melts back ... the high trails. The winter of 2014-2015, according to ... very different. For the first time ever many high ...
Breaking Medicine News(10 mins):Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 2Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 3Health News:Mesothelioma Foundation to speak at BoRit Asbestos Superfund Citizen Advisory Group Meeting 2Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 2Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 3Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 4Health News:2014-15 winter drought offers unique opportunity for Oregon and California hikers and backpackers reports fresh water advocate 2Health News:2014-15 winter drought offers unique opportunity for Oregon and California hikers and backpackers reports fresh water advocate 3
... 7 Natural Alternatives International, Inc. ("NAI") (Nasdaq: ... and marketer of customized nutritional supplements, today announced ... Randell Weaver,s employment with NAI ended.NAI also announced ... with Wells Fargo Bank. Among other changes ...
... Legislation Aimed at Protecting Medicare Beneficiaries Introduced on ... 7 Physical therapy ... limited by arbitrary financial caps under legislation introduced ... according to the American Physical Therapy Association (APTA). ...
... Acute lymphoblastic leukemia is most common pediatric cancer , , ... leukemia cells predicts which children with acute lymphoblastic leukemia ... online Jan. 7 in the New England Journal ... physicians fine-tune treatment for different subsets of patients. , ...
... SB 203, known as Emily,s Law, has received ... in the state of Ohio. Named after Emily Jerry, ... pharmacy technicians. The law, which was originally sponsored by ... National Pharmacy Technician Association. Emily,s Story , Emily ...
... used to treat heart failure, slowed cell growth, study ... a drug used for many years to treat irregular ... cancer-fighting agent, researchers report. , Cancer cells need to ... these cells are oxygen-deprived and need to switch on ...
... A medical revolution emerges when,technology blends with smart ... new Smart OR(TM) - a specialized neurosurgical suite ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20081016/CLTH057 ... configuration of advanced imagery and mapping technology, the ...
Cached Medicine News:Health News:Natural Alternatives International, Inc. Announces Change in Executive Officer and Loan Modification and Extension 2Health News:Senate and House Introduce Legislation to Repeal Therapy Caps 2Health News:Senate and House Introduce Legislation to Repeal Therapy Caps 3Health News:Gene Governs Response to Leukemia Chemotherapy 2Health News:Emily's Law for Regulating Pharmacy Technicians Signed by Ohio Governor 2Health News:Emily's Law for Regulating Pharmacy Technicians Signed by Ohio Governor 3Health News:Heart Drug May Be a Cancer Fighter 2Health News:A New, 'Smart' Approach to Brain and Spine Surgery 2Health News:A New, 'Smart' Approach to Brain and Spine Surgery 3
(Date:3/30/2015)... , March 30, 2015 ... My Diabetes Emergency Plan at the 2015 @NatHurricaneCon ... to be prepared to manage your #diabetes before emergencies ... (ACE) – the charitable, educational and scientific arm of ... joined forces with Lilly Diabetes to share the ...
(Date:3/30/2015)... 2015  The investigational S- equol nutritional supplement ... symptoms, such as hot flashes, according to a new ... Health .[i] "Current data suggest that women ... vasomotor symptoms and possibly additional benefits, such as skin ... equol, physicians and health care professionals may consider the ...
(Date:3/30/2015)... WHITE PLAINS, N.Y. , March 30, 2015 /PRNewswire-USNewswire/ ... developing new treatments for patients with a rare and ... from a recent licensing agreement with a new biotechnology ... has been funding this work, led by Assistant Professor ... Tomasz Cierpicki , Ph.D., at the University of Michigan, ...
Breaking Medicine Technology:Preparation Is Personal for Those with Chronic Illnesses 2Preparation Is Personal for Those with Chronic Illnesses 3Preparation Is Personal for Those with Chronic Illnesses 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 2New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 3New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 5New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 6Leukemia Research Funded by The Leukemia & Lymphoma Society Gets Infusion of Support from Startup Biotechnology Company 2Leukemia Research Funded by The Leukemia & Lymphoma Society Gets Infusion of Support from Startup Biotechnology Company 3
... -- ImClone,Systems Incorporated and Bristol-Myers Squibb Company ... ERBITUX(R) (Cetuximab) plus,gemcitabine (a chemotherapy) in patients ... did not meet its,primary endpoint of improving ... Oncology Group (SWOG), a cancer,center network sponsored ...
... ALTO, Calif., April 09, 2007 /PRNewswire-FirstCall/ --,Telik, ... its,multicenter Phase 2 trial of the triplet ... paclitaxel will be,presented at the 98th annual ... (AACR) in Los Angeles. Preclinical studies of,cellular ...
Cached Medicine Technology:Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 2Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 3
... an in-vitro diagnostic test kit for ... cruzi in human serum/plasma. This test ... using gelatin particles coated with inactivated ... particles are agglutinated in the presence ...
The Cellabs T. cruzi IgG CELISA is a direct ELISA kit designed to detect antibodies produced during T. cruzi infections (Chagas disease)....
Inquire...
Silicone ICD lead...
Medicine Products: